| Document and Entity Information - USD ($) | 3 Months Ended | |
| Sep. 30, 2018 | Dec. 31, 2017 | |
| Document and Entity Information: | ||
| Entity Registrant Name | SANGUI BIOTECH INTERNATIONAL INC | |
| Document Type | 10-Q | |
| Document Period End Date | Sep. 30, 2018 | |
| Trading Symbol | sgbi | |
| Amendment Flag | false | |
| Entity Central Index Key | 1,104,280 | |
| Current Fiscal Year End Date | --06-30 | |
| Entity Common Stock, Shares Outstanding | 197,897,747 | |
| Entity Public Float | $ 197,897,747 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Current Reporting Status | No | |
| Entity Voluntary Filers | No | |
| Entity Well-known Seasoned Issuer | No | |
| Document Fiscal Year Focus | 2,019 | |
| Document Fiscal Period Focus | Q1 |
| Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2018 | Jun. 30, 2018 |
| CURRENT ASSETS | ||
| Cash | $ 49,798 | $ 20,943 |
| Prepaid expenses and other assets | 27,769 | 22,774 |
| Tax refunds receivable | 100,560 | 2,143 |
| Accounts receivable, net | 476 | 49,107 |
| Note receivable, related party | 815 | 7,062 |
| Total Current Assets | 179,418 | 102,029 |
| TOTAL ASSETS | 179,418 | 102,029 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | 200,391 | 189,739 |
| Accrued interest - related party | 21,061 | 19,088 |
| Note payable | 40,025 | |
| Notes payable - related party | 384,315 | 204,321 |
| Total Current Liabilities | 605,767 | 453,173 |
| STOCKHOLDERS' EQUITY (Deficit) | ||
| Common stock value | 32,884,893 | 32,864,356 |
| Additional paid-in capital | 4,513,328 | 4,513,328 |
| Accumulated deficit | (37,270,071) | (37,180,108) |
| Total Stockholders' Equity (Deficit) | (426,349) | (351,144) |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | $ 179,418 | $ 102,029 |
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) | 3 Months Ended | |
| Sep. 30, 2018 | Sep. 30, 2017 | |
| REVENUES | ||
| revenues | $ 11,272 | $ 16,636 |
| COST OF SALES | 73 | 4 |
| GROSS MARGIN | 11,199 | 16,632 |
| OPERATING EXPENSES | ||
| Research and development | 7,972 | 4,629 |
| Professional fees | 49,934 | 39,578 |
| General and administrative | 46,791 | 30,214 |
| Total Operating Expenses | 104,697 | 74,421 |
| OTHER INCOME (EXPENSE) | ||
| Gain (Loss) of foreign exchange | 1,062 | (4,494) |
| Interest expense | (3,691) | (1,868) |
| Total other income (expense) | (2,629) | (6,362) |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||
| Foreign currency translation adjustments | 385 | (24,760) |
| COMPREHENSIVE INCOME (LOSS) | $ (95,742) | $ (88,911) |
| BASIC AND DILUTED LOSS PER SHARE | $ 0 | $ 0 |
| BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | 192,661,180 | 185,764,406 |
| Condensed Consolidated Statements of Cash Flows - USD ($) | 3 Months Ended | |
| Sep. 30, 2018 | Sep. 30, 2017 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Profit loss | $ (96,127) | $ (64,151) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Foreign currency exchange transactions | (1,062) | 4,053 |
| Changes in operating assets and liabilities | ||
| Trade accounts receivable | 48,430 | |
| Prepaid expenses and other current assets | (5,299) | 3,430 |
| Tax refunds receivable | (98,291) | (1,382) |
| Accounts payable and accrued expenses | 10,416 | 12,953 |
| Related party advances | 6,217 | 1,923 |
| Related party accounts payable | 1,972 | |
| Net Cash Used in Operating Activities | (133,744) | (43,174) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from related party note payable | 668,692 | |
| Prepayment of related party note payable | (488,374) | |
| Proceeds from common stock issued for cash | 20,537 | 59,399 |
| Prepayment notes payable | (38,329) | |
| Net Cash Provided by Financing Activities | 162,526 | 59,399 |
| EFFECTS OF EXCHANGE RATES | 73 | (21,143) |
| NET INCREASE (DECREASE) IN CASH | 28,855 | (4,918) |
| CASH AT BEGINNING OF PERIOD | 20,943 | 56,990 |
| CASH AT END OF PERIOD | $ 49,798 | $ 52,072 |
| Note 1 - Basis of Presentation | 3 Months Ended |
| Sep. 30, 2018 | |
| Notes | |
| Note 1 - Basis of Presentation | NOTE 1 - BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2018. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three - month period ended September 30, 2018 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2019. |
| Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
| Sep. 30, 2018 | |
| Notes | |
| Note 2 - Summary of Significant Accounting Policies | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its ninety-percent-owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Witten, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive income (loss) and accumulated in a separate component of stockholders' equity. Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of September 30, 2018 and June 30, 2018 and our unaudited consolidated statements of operations for the three month period ended September 30, 2018 and 2017, were calculated as follows: The Company accounts for the translations denominated in foreign currencies in the Parent Companys books as transaction gains (losses) recognized in Other income / Other expenses. Risk and Uncertainties The Company's line of future pharmaceutical products (artificial oxygen carriers or blood substitute and additives) and medical products (wound dressings and other wound management products) being developed by Sangui GmbH, are deemed as medical devices or biologics, and as such are governed by the Federal Food and Drug and Cosmetics Act and by the regulations of state agencies and various foreign government agencies. The pharmaceutical, under development in Germany, will be subject to more stringent regulatory requirements, because they are in vivo products for humans. The Company and its subsidiaries have no experience in obtaining regulatory clearance on these types of products. Therefore, the Company will be subject to the risks of delays in obtaining or failing to obtain regulatory clearance. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $ 37,270,071 96,127 133,744 Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts. Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred. Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company derives revenue primarily from licensing fees on sales of its wound spray product. The licensing fees are invoiced on a quarterly basis and are recognized as revenues during the quarter for which the sales were reported by the licensee. The conditions of ASC 606 are met and the Company records revenues when : (i) a valid license arrangement exists, (ii) the license terms are fixed and determinable, (iii) the later of (a) when the licensee makes the subsequent sales or use that trigger the royalty or (b) the performance obligation to which some or all of the sales-based or usage- based royalties has been allocated has been satisfied and (iv) collectability is probable. Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of September 30, 2018, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive. Comprehensive Income (Loss) Total comprehensive income (loss) represents the net change in stockholders' equity during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive income (loss) is limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity. Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. |
| Note 3 - Commitments and Contingencies | 3 Months Ended |
| Sep. 30, 2018 | |
| Notes | |
| Note 3 - Commitments and Contingencies | NOTE 3 - COMMITMENTS AND CONTINGENCIES Litigation The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a material effect on the Company's financial position or results of operations. Indemnities and Guarantees During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet. Leases The Company leases office facilities in Witten/Germany from a unrelated third party for Euro 2,460 per month. The office lease contracts are maintained on a month-to-month basis. The Company also leases office facilities in Hamburg/Germany from a unrelated third party for the period from September 1, 2018 to June 30, 2019, with an automatic extension to January 31, 2020, if not terminated 90 days before June 30, 2019 for Euro 670 per month. The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month beginning June 2018 expiring May 2020. |
| Note 4 - Debt | 3 Months Ended |
| Sep. 30, 2018 | |
| Notes | |
| Note 4 - Debt | NOTE 4 DEBT Notes Payable Related Parties Prior to 2016, the Company entered into a note payable with a Company Director for 100,000 Euros ($ 116,215 19,718 On December 12, 2017 a Company Director advanced an amount of 25,000 Euros ($ 29,054 465 On January 19, 2018 a Company Director advanced an amount of 25,000 Euros ($ 29,054 404 On March 13, 2018 a Company Director advanced an amount of 25,000 Euros ($ 29,054 320 On July 12, 2018 a Company Director advanced an amount of 420,000 Euros ($ 488,103 759 On July 12, 2018 a Company Director advanced an amount of 80,000 92,832 806 On July 16, 2018 a Company Director advanced an amount of 25,000 Euros ($ 29,054 121 On September 10, 2018 a Company Director advanced an amount of 25,000 Euros ($ 29,054 32 On September 28, 2018 a Company Director advanced an amount of 25,000 Euros ($29,054 as of September 30, 2018) to the Company. The loan is due on demand, accrues no interest and is unsecured. The Company has fully repaid the loan on October 1, 2018. Notes payable On June 15, 2015 the Company entered into an unsecured note for 32,963 Euros and accrues interest annually at 4%. The note was originally entered into with a related-party. As of June 30, 2018, due to a change in nature of relationship with the note holder, the Company has discontinued recording it as a related party obligation. As of June 30, 2018, the principle and accrued interest of the note was $ 40,025 |
| Note 5 - Capital Stock | 3 Months Ended |
| Sep. 30, 2018 | |
| Notes | |
| Note 5 - Capital Stock | NOTE 5 CAPITAL STOCK Preferred Stock Common Stock 192,951,503 191,951,503 192,897,747 191,897,747 During the three months ended September 30, 2018, the Company issued 1,000,000 20,537 Treasury Stock 53,756 19,387 |
| Note 6 - Subsequent Events | 3 Months Ended |
| Sep. 30, 2018 | |
| Notes | |
| Note 6 - Subsequent Events | NOTE 6 SUBSEQUENT EVENTS Subsequent to September 30, 2018, the Company issued 5,000,000 0.0115 57,302 Subsequent to September 30, 2018 a Company Director advanced an amount of 25,000 Euros ($29,054; converted with exchange rate of September 30, 2018) to the Company. The loan is due on demand, accrues interest annually at 2% and is unsecured. In accordance with ASC 855-10, the Companys management has reviewed all material events and there are no additional material subsequent events to report. |
